AlgoTherapeutix
French tech company | Builders Republic
About
Biotech company developing topical formulations of repositioned analgesic compounds to treat intense peripheral neuropathic pain caused by chemotherapy — lead asset ATX01 completed a Phase 2 international clinical trial (ACT) in patients with chemotherapy-induced peripheral neuropathy (CIPN).
Key facts
- Status
- Active
- Sectors
- Healthcare & Life Sciences
- Latest stage
- Series A
- Founded
- 2018
- City
- SURESNES
- Region
- IDF
- Tracked rounds
- 1
- Amount raised
- 12 M€ raised since 2020
Funding rounds
- Series A — 2020
Investors
- bpifrance
- Omnes Capital